Native vessel PCI in the diabetic: DES whenever feasible

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 5, 2008, Pages 608-609

  Hillegass, William ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PACLITAXEL; PRASUGREL; RAPAMYCIN; TICAGRELOR; METAL;

ANGIOCARDIOGRAPHY; BARE METAL STENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; EDITORIAL; FEASIBILITY STUDY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; RESTENOSIS; STENT THROMBOSIS; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; INSTRUMENTATION; MORTALITY; NOTE; PROSTHESIS; RADIOGRAPHY; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; METALS; PROSTHESIS DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 58749086424     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21826     Document Type: Editorial

References (11)

1. Harrington RA, Ohman EM. The enigma of drug-eluting stents: Hope, hype, humility, and advancing patient care. JAMA 2007;297:2028-2030.
2. Chan C. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: The DECODE study. Catheter Cardiovasc Interv (in press).
3. Kim J-S. Comparison of sirolimus-eluting stent and paclitax-eleluting stent for long-term cardiac adverse events in diabetic patients: The Korean Multicenter Angioplasty Team (KOMATE) Registry. Catheter Cardiovasc Interv (in press).
4. Moses JW, Leon MB, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
5. Stone GW, Ellis SG, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
6. Sabate M, Jimenez-Quevedo P, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112: 2175-2183.
7. Machecourt J, Danchin N, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007;50:501-508.
8. Geisler T, Gawaz M. [Resistance to antiplatelet substances - A real clinical problem.] Herz 2008;33:260-268.
9. Angiolillo DJ, Shoemaker SB, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-716.
10. Mahmud E, Bromberg-Marin G, et al. Clinical efficacy of drug-eluting stents in diabetic patients: A meta-analysis. J Am Coll Cardiol 2008;51:2385-2395.
11. Bonello L, Paganelli F, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-1636.